Spinal Muscular Atrophy Treatment Market Growth Fuelled by Zolgensma®, Spinraza®, and Early Newborn Screening | Pipeline Innovation & Market Size Forecast

"The global spinal muscular atrophy treatment market reached USD 4.40 billion in 2024 and is expected to reach approximately USD 10.09 billion by 2030, growing at a CAGR of 18.0% during the forecast period 2025-2030," according to DataM Intelligence.

Key players in the Spinal Muscular Atrophy Treatment Market include Novartis AG (Zolgensma®), F. Hoffmann-La Roche Ltd (Evrysdi®), Genentech USA, Biogen Inc. (Spinraza®), PTC Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Biohaven Ltd, Voyager Therapeutics, Inc., Catalent, Inc., Pfizer Inc., and others. These industry leaders are driving SMA innovation through gene therapy, antisense oligonucleotides, oral modulators, and next-generation pipeline assets expanding indication range and access.

Download your exclusive sample report today: https://www.datamintelligence.com/download-sample/spinal-muscular-atrophy-sma-treatment-market?jd

Spinal Muscular Atrophy Treatment Market M&A & Strategic Collaborations

• In May 2025, Biogen partnered with Voyager Therapeutics to co-develop next-generation intrathecal gene therapy platforms for SMA, enhancing vector delivery capabilities.
• In June 2025, Novartis announced a licensing deal with Ionis Pharmaceuticals for a new small-molecule modulator targeting muscular function improvement in adolescent SMA patients.
• Genentech expanded its SMA center of excellence in Boston via a strategic investment, enhancing clinical trial infrastructure and patient outreach.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/spinal-muscular-atrophy-sma-treatment-market?jd

Key Growth Drivers & Emerging Opportunities in the Spinal Muscular Atrophy Treatment Market

• Expanded newborn screening programs globally, enabling early detection and timely treatment initiation.
• Gene therapies (Zolgensma®, Evrysdi®) offering durable outcomes with single-dose or daily oral regimens.
• Antisense oligonucleotide advancements enhancing efficacy and targeting SMN2 splicing.
• R&D investment in next-gen delivery systems, including CNS-targeted vectors and oral small molecules.
• Emerging indications in adult and late-onset SMA, broadening patient demographic.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=spinal-muscular-atrophy-sma-treatment-market?jd

Regional Market Drivers in the Spinal Muscular Atrophy Treatment Market

North America leads with widespread SMA screening mandates, high uptake of Zolgensma® and Spinraza®, and strong payer support.
Europe follows with progressive orphan drug policies, growing access programs, and expanded indication approvals.
Asia-Pacific is fast emerging, with government initiatives, registry development, and generics/local manufacturing beginning to scale.
Latin America & MEA are in early stages, with increased advocacy, infrastructure building, and inclusion in global research networks.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?jd

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis for Drug Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?jd

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.